Skip to main content

Advertisement

Table 2 Immunoreactivity of KGH-R1 mAb in human tumours and corresponding normal tissues

From: A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues

Tumour Cases Immunoreactivity (HSCOREsa)
Primary tumour tissues Normal tissues
Colorectal cancer 30 208.69 ± 84.40 6.88 ± 1.53
Gastric cancer 30 155.29 ± 87.50 7.86 ± 2.79
Oesophageal cancer 30 163.73 ± 66.00 8.50 ± 3.28
Bladder cancer 30 146.76 ± 95.36 8.10 ± 2.43
Lung adenocarcinoma 30 238.63 ± 72.00 7.00 ± 1.77
Lung squamous cell carcinoma 30 178.26 ± 83.99 7.00 ± 1.77
Lung small cell carcinoma 30 134.38 ± 91.58 7.00 ± 1.77
Papillary thyroid carcinoma 30 239.33 ± 75.51 8.43 ± 2.32
Hepatocarcinoma 30 184.38 ± 96.75 11.29 ± 5.51
Prostate carcinoma 30 114.77 ± 70.59 13.00 ± 4.24
Breast cancer 30 197.46 ± 56.33 9.23 ± 3.19
Endometrial cancer 30 139.29 ± 86.00 15.75 ± 5.72
Glioma 30 97.60 ± 8.85 17.30 ± 8.32
Renal cell carcinoma 30 117.50 ± 73.86 16.00 ± 5.85
  1. aMean ± SD